Drug Trial Radar · NCT05685732
An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD
Last checked: Nov 19, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
246
Actual
Start
Mar 22, 2023
Primary completion
May 2, 2024
Study completion May 2, 2024
Sponsor
- Lead sponsor
- Corium, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Premier Research; Prometrika, LLC; Almac
- First posted
- Jan 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, dose-optimized, randomized, double-blind, placebo controlled, efficacy and safety study with Azstarys® in children 4 to 12 years of age with attention-deficit/hyperactivity disorder (ADHD). Azstarys® contains dexmethylphenidate (d-MPH) and serdexmethylphenidate (SDX), a prodrug of d-MPH and is orally administered. The primary objective is to determine the efficacy of Azstarys® compared to placebo in treating children ages 4 to 12 years old with ADHD. The study will consist of two randomized and blinded treatment cohorts ages 4 to 5 years of age and 6 to 12 years of age. Randomization will be applied separately with a starting dose up-titration at different dose levels for each cohort. 130 and 100 subjects will be enrolled, respectively. Approximately 20 sites will participate.
Conditions
- Attention Deficit/Hyperactivity Disorder
Interventions
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)Drug
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
placeboOther
matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- A Comparison of the Change in Mean ADHD Rating Scale (ADHD-RS) Results From Baseline to End of Treatment Between Active and Placebo Treatments.Time frame: 4 weeks
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Preferred Research Partners (PRP)
Little Rock, Arkansas
Advanced Research Center (ARC)
Anaheim, California
IMMUNOe International Research Center
Centennial, Colorado
Clinical Neuroscience Solutions - Jacksonville
Jacksonville, Florida
Accel Research Sites - Lakeland
Lakeland, Florida
Accel Research Sites - Maitland
Maitland, Florida
South Florida Research Phase I-IV INC
Miami Springs, Florida
CNS Healthcare - Orlando
Orlando, Florida
Sky Clinical Research Network Group P.C.
Atlanta, Georgia
CenExel IResearch, LLC - Decatur
Decatur, Georgia
CenExel iResearch, LLC
Savannah, Georgia
DelRicht Research - Touro Medical Center
New Orleans, Louisiana
St Charles Psychiatric Associates & Midwest Research Group
Saint Charles, Missouri
Boeson Research
Missoula, Montana
Alivation Research, LLC
Lincoln, Nebraska
Center for Psychiatry and Behavioral Medicine Inc
Las Vegas, Nevada
Clinical Neuroscience Solutions--Memphis
Memphis, Tennessee
Houston Clinical Trials
Bellaire, Texas
AIM Trials
Plano, Texas
Flourish Research
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.